Tuesday, December 14, 2021

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Developing Safer, More Effective Psilocybin Therapies for Patients

 Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs. A recent article quotes CEO Doug Drysdale as saying, “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental health care, but few companies have addressed the well-known limitations and side effects of oral psilocybin… Cybin has always strived to develop safer and more effective therapies for patients, which has guided our multiple psilocybin programs: CYB001, CYB001 and CYB003.” The positive CYB003 preclinical findings demonstrate distinctive advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. The CYB003 program is designed to maintain the benefits of oral psilocybin, which, according to previous research, appears to be efficacious in treating mental health disorders while addressing associated challenges, including the slow onset of action, extended duration of effect and variability in response among patients.

To view the full article, visit https://ibn.fm/bUmGU

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN        

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: